Boehringer Ingelheim reported new and updated data from the Beamion LUNG-1 trial evaluating zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer ...

With an investment reportedly approaching $400 million, the manufacturing plant will be built in two phases with phase one ...

The key here is that the new battery is semi-solid-state (note not fully solid-state), which uses a stable, gel-like material ...

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and ...